<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2818">
  <stage>Registered</stage>
  <submitdate>7/06/2010</submitdate>
  <approvaldate>7/06/2010</approvaldate>
  <nctid>NCT01145560</nctid>
  <trial_identification>
    <studytitle>A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock</studytitle>
    <scientifictitle>A MultiCentre, Randomized, Double-blind, Placebo-controlled Phase IIb Study to Compare the Efficacy and Safety of Two Dosing Regimens of Intravenous Infusions of AZD9773 (CytoFab) in Adult Patients With Severe Sepsis and/or Septic Shock</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>D0620C00003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Severe Sepsis</healthcondition>
    <healthcondition>Septic Shock</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Poisoning</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AZD9773
Treatment: drugs - Placebo

Experimental: 1 - AZD9773 250/50 units/kg

Experimental: 2 - AZD9773 500/100 units/kg

Placebo Comparator: 3 - 


Treatment: drugs: AZD9773
A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days

Treatment: drugs: Placebo
Placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Ventilator-free Days (VFDs) Over 28 Days - Number of ventilator-free days (VFDs)</outcome>
      <timepoint>Over 28 days following first dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>7-day Mortality - Number of patients who died over 7 days</outcome>
      <timepoint>Over 7 days following first dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>28-day Mortality - Number of patients who died over 28 days</outcome>
      <timepoint>Over 28 days following first dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and Tolerability - Number of patients with treatment-emergent adverse events</outcome>
      <timepoint>All study visits (over 90 days following first dose)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adults with a first episode of sepsis during this hospitalisation and objective
             evidence of infection that requires parenteral antibiotics.

          -  At least 2 of 4 SIRS criteria in the 24 hours before organ dysfunction (must include
             either fever OR elevated white blood cells [WBC])

          -  Cardiovascular or respiratory dysfunction.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Immunocompromising comorbidities or concomitant medications:

               1. Advanced human immunodeficiency virus (HIV) infection (CD4 =50/mm3).

               2. Stage III or IV cancer.

               3. Haemopoietic or lymphoreticular malignancies not in remission.

               4. Receiving radiation therapy or chemotherapy.

               5. Stem cell, organ or bone marrow transplant in the past 6 months.

               6. Absolute neutrophil count &lt;500 per ÂµL.

               7. High dose steroids or other immunocompromising drugs.

          -  Concomitant diseases:

               1. Deep seated fungal infection or active tuberculosis.

               2. Cirrhosis with portal hypertension or Childs-Pugh Class C.

               3. History of chronic hypercarbia, respiratory failure in past 6 months or use of
                  home oxygen in the setting of severe chronic respiratory disease.

               4. Neuromuscular disorders that impact breathing/spontaneous ventilation.

               5. Quadriplegia.

               6. Cardiac arrest in the past 30 days.

               7. New York Heart Association functional Class IV due to heart failure or any
                  disorder.

               8. Burns over &gt; 30% of body surface area.

          -  Medication and allergy disqualifications.

               1. Treatment with anti-TNF agents within the last 8 weeks.

               2. Previously received ovine derived products (CroFab, DigiFab).

               3. Sheep product allergy or allergy to latex, papain, chymopapain.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>300</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Research Site - Blacktown</hospital>
    <hospital>Research Site - Wollongong</hospital>
    <hospital>Research Site - Herston</hospital>
    <hospital>Research Site - Nambour</hospital>
    <hospital>Research Site - Woollongabba</hospital>
    <hospital>Research Site - Adelaide</hospital>
    <hospital>Research Site - Clayton</hospital>
    <hospital>Research Site - Footscray</hospital>
    <hospital>Research Site - Fremantle</hospital>
    <postcode> - Blacktown</postcode>
    <postcode> - Wollongong</postcode>
    <postcode> - Herston</postcode>
    <postcode> - Nambour</postcode>
    <postcode> - Woollongabba</postcode>
    <postcode> - Adelaide</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Footscray</postcode>
    <postcode> - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Genk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Godinne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Ottignies</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Usti Nad Labem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kuopio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Angers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Roche Sur Yon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Limoges</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montauban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nimes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Orleans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poitiers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-michel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre Les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Asturias</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cataluna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Comunidad Valenciana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Coruna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Islas Baleares</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study to evaluate the effect of two different doses of AZD9773
      (CytoFab) versus placebo on ventilator free days (VFDs) over the first 28 days after the
      start of dosing with AZD9773 in patients with severe sepsis and/or septic shock, who are
      already receiving appropriate standard of care treatment for sepsis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01145560</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gordon Bernard, MD</name>
      <address>Vanderbilt University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>